Michael Burkes Brophy Sells 496 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

by · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 496 shares of the company’s stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $119.09, for a total value of $59,068.64. Following the completion of the transaction, the chief financial officer now directly owns 74,314 shares in the company, valued at approximately $8,850,054.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

  • On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total value of $82,097.71.
  • On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $73,422.08.
  • On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90.
  • On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $102.77, for a total transaction of $127,229.26.
  • On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The stock was sold at an average price of $105.29, for a total transaction of $72,650.10.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $117.67 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54. The firm has a market capitalization of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. The business’s 50 day moving average price is $123.24 and its 200-day moving average price is $111.24.

Natera (NASDAQ:NTRA – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same quarter in the previous year, the company posted ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. As a group, equities research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Trading of Natera

Several large investors have recently bought and sold shares of NTRA. Farallon Capital Management LLC lifted its stake in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares in the last quarter. First Light Asset Management LLC lifted its position in Natera by 295.9% during the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after buying an additional 490,822 shares in the last quarter. AQR Capital Management LLC lifted its position in Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after buying an additional 469,327 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new position in Natera during the first quarter worth $33,938,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Natera in the 1st quarter valued at $33,956,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. Leerink Partners increased their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. The Goldman Sachs Group lifted their price target on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Piper Sandler restated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday. Finally, TD Cowen boosted their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Read Our Latest Stock Report on NTRA

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Recommended Stories